Jiuyuan Gene (02566) surged over 13%, reaching 13.42% as of press time, at HK$4.31, with a turnover of HK$369,800.
On the news front, Jiuyuan Gene recently announced that the Investigational New Drug (IND) application for its independently developed Class 1 new drug JY54-2 Injection has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. This IND application covers two indications: type 2 diabetes and weight management for obese or overweight populations.
The company plans to conduct a Phase I clinical study of JY54-2 Injection, which aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JY54-2 Injection in trial participants, providing a basis for subsequent clinical development in the aforementioned two indications.
JY54-2 Injection is a long-acting amylin analog independently developed by the company. This product is a next-generation pH-neutral stable long-acting amylin analog with the potential to be developed into combination formulations with other metabolic drugs such as GLP-1 products. Preclinical trial data show that JY54-2 Injection has demonstrated excellent performance across various indicators in multiple pharmacodynamic and safety studies. Based on its molecular design characteristics and mechanism of action analysis, JY54-2 Injection is expected to support long-acting dosing regimens and demonstrate differentiated clinical application potential in the field of weight management.
Comments